Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3

被引：0

作者：

Mazieres, J. ^{[1
]}

Duruisseaux, M. ^{[2
,3
,4
]}

Curcio, H. ^{[5
]}

Morizane, C. ^{[6
]}

Galot, R. ^{[7
,8
]}

Rottey, S. ^{[9
]}

Stratmann, J. A. ^{[10
]}

Ma, Y. ^{[11
]}

Bouzaggou, M. ^{[12
]}

Geng, L. ^{[13
]}

Wermke, M. ^{[14
]}

机构：

[1] Ctr Hosp Univ Toulouse, Thorac Oncol Dept, Toulouse, France

[2] Hosp Civils Lyon, Louis Pradel Hosp, Resp Med & Early Phase, Canc Inst, Lyon, France

[3] Canc Res Ctr Lyon, UMR INSERM 1052, CNRS 5286, Lyon, France

[4] Univ Lyon, Claude Bernard Univ Lyon 1, Lyon, France

[5] Ctr Francois Baclesse, Oncol Dept, Caen, France

[6] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[7] Univ Catholique Louvain UCLouvain, Brussels, Belgium

[8] Clin Univ St Luc, Inst Roi Albert II, Brussles, Belgium

[9] Ghent Univ Hosp, Drug Res Unit, Ghent, Belgium

[10] Goethe Univ, Hematol Oncol, Frankfurt, Germany

[11] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany

[12] Boehringer Ingelheim France SAS, Global Clin Dev & Operat, Reims, France

[13] Boehringer Ingelheim China Investment Co, Global Biostat Data Sci, Shanghai, Peoples R China

[14] TU Dresden Univ Technol, NCT UCC Early Clin Trial Unit, Dresden, Germany

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.1258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2028TiP

引用

页码：S1076 / S1077

页数：2